Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Assessing Patient Impact From Recalls Often A Judgment Call, US FDA Says

Executive Summary

Industry participants on an FDA-convened webinar asked for further guidance on how to evaluate the effects enforcement actions might have on patients and the public health. The webinar was organized to discuss a recent FDA draft guidance on benefit-risk considerations for post-market decisions.


Related Content

FDA Finalizes Post-Market Benefit-Risk Guidance
FDA, AAMI Explore How To Consider Benefits, Risks In Postmarket





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts